world-biomarkers-pharma-biotech-2017-posters

16 / 61

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 72
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
A framework for selecting analytical biomarkers: A first principles approach
Samantha A Byrnes and Bernhard H Weigl
Intellectual Ventures Laboratory, USA
Biomarkers are objective indications of a medical state that can be measured accurately and reproducibly. Traditional
biomarkers enable diagnosis of disease through detection of disease-specific molecular signatures or distinct physiological
or anatomical signatures. Appropriate selection of biomarkers with innovative test design can transform patient care by
providing earlier diagnosis, treatment monitoring, and ultimately reduced burden of disease. These results will be best achieved
through collaborations between researchers, device designers, and clinicians to drive test development for addressing clinical
questions. We developed a framework for selecting biomarkers that are most likely to provide useful information about a
patient’s disease state. This framework describes the trade-offs between biomarkers’ sensitivity/specificity for a disease-causing
agent, the complexity of detection, and how this knowledge can be applied to the development of diagnostic tests. This report
also details assessment criteria for successful tests. Our framework aims to assist stakeholders from test developers to clinicians
by focusing on validating biomarker selection for an explicit clinical question (e.g., direct correlation with pathogenesis)
followed by test development expediency (e.g., ease of detection). There are few, if any, ideal biomarkers due to trade-offs
based on performance, cost, and usability. It is important to consider how and where a test will be used in order to select an
appropriate biomarker. Our framework is intended to help assess these trade-offs to design new systems and enhance those
that are already available.
Biography
Samantha A Byrnes completed her PhD in Bioengineering and MPH in Global Health Metrics at the University of Washington, Seattle. She has lived and worked in
developing settings which has included the testing of a nucleic acid purification and storage prototype in Nicaragua and she is helping to develop an assessment
framework for a vaccination campaign in Bangladesh. Currently, she works for Intellectual Ventures Laboratory focusing on development of products for rapid
disease diagnosis and biomarker selection.
Samantha A Byrnes et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110